Actinium Pharmaceuticals Inc. (ATNM)’s Financial Results Comparing With Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)

As Biotechnology companies, Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) are our subject to compare. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actinium Pharmaceuticals Inc. N/A 0.00 N/A -0.20 0.00
Deciphera Pharmaceuticals Inc. 25 55.14 N/A -3.40 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Actinium Pharmaceuticals Inc. 0.00% -213.7% -140.7%
Deciphera Pharmaceuticals Inc. 0.00% -43.4% -38.7%

Liquidity

Actinium Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 1.8 and 1.8 respectively. The Current Ratio and Quick Ratio of its competitor Deciphera Pharmaceuticals Inc. are 9.6 and 9.6 respectively. Deciphera Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Actinium Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for Actinium Pharmaceuticals Inc. and Deciphera Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Actinium Pharmaceuticals Inc. 0 0 0 0.00
Deciphera Pharmaceuticals Inc. 0 0 2 3.00

Deciphera Pharmaceuticals Inc. on the other hand boasts of a $60 consensus price target and a 66.34% potential upside.

Institutional and Insider Ownership

Institutional investors owned 17.6% of Actinium Pharmaceuticals Inc. shares and 60.9% of Deciphera Pharmaceuticals Inc. shares. About 0.1% of Actinium Pharmaceuticals Inc.’s share are owned by insiders. Insiders Competitively, owned 0.2% of Deciphera Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Actinium Pharmaceuticals Inc. -7.69% -4.98% -21.93% -58.43% -63.91% -39.84%
Deciphera Pharmaceuticals Inc. 0.87% -7.92% -3.62% -16.13% -34.17% 5.29%

For the past year Actinium Pharmaceuticals Inc. has -39.84% weaker performance while Deciphera Pharmaceuticals Inc. has 5.29% stronger performance.

Summary

On 7 of the 8 factors Deciphera Pharmaceuticals Inc. beats Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.